Drug
Delandistrogene Moxeparvovec
Delandistrogene Moxeparvovec: highest development phase Phase 3, developed by Roche, Sarepta Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche, Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| delandistrogene moxeparvovec NCT05096221 | Phase 3 | Duchenne Muscular Dystrophy |
| delandistrogene moxeparvovec NCT05967351 | Phase 3 | Duchenne Muscular Dystrophy |
| delandistrogene moxeparvovec NCT05881408 | Phase 3 | Duchenne Muscular Dystrophy |
| delandistrogene moxeparvovec NCT06128564 | Phase 2 | Duchenne Muscular Dystrophy |
| delandistrogene moxeparvovec NCT03375164 | Phase 1/2 | Duchenne Muscular Dystrophy |
| delandistrogene moxeparvovec NCT06241950 | Phase 1 | Duchenne Muscular Dystrophy |
| delandistrogene moxeparvovec NCT04626674 | Phase 1 | Duchenne Muscular Dystrophy |
| delandistrogene moxeparvovec NCT06597656 | Phase 1 | Duchenne Muscular Dystrophy |
Latest
No recent events.
Follow Delandistrogene Moxeparvovec on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.